This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Bristol-Myers Squibbs performance against key rivals in the ethical pharmaceutical sector
- Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry
- Investigate the strength of BMSs pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.
